Share the article

Part 3: Innovation of Antibiotics and the Dilemma of Access and Excess

The discovery void

Learn about the reasons behind the modest development of new antibiotics.

New business models addressing antibiotic resistance

Learn about the need to generate new collaborative business models addressing antibiotic resistance.

The access and excess dilemma

Learn about the dilemma of access and excess to antibiotics in low- and middle-income countries.


Here, you can download a reference list for the third part of the course:

Reference list, part 3